26 results about "Antigen binding site" patented technology

The present invention relates to: a receptor tyrosine kinase like orphan receptor 1 (ROR 1) antibody or an antigen-binding fragment thereof; a nucleic acid encoding same; a recombinant expression vector carrying the nucleic acid; a host cell transinfected with the recombinant expression vector; a method for preparing the antibody or the antigen-binding fragment thereof; a bi- or multi-specific antibody bearing the antibody or the antigen-binding fragment thereof; an immune cell-engaging bi- or multi-specific antibody; an antibody-drug conjugate (ADC) in which the antibody or the antigen-binding fragment thereof is bound to a drug; a chimeric antigen receptor (CAR) containing the scFv of the antibody as an antigen-binding site of an extracellular domain; an immune cell having the chimeric antigen receptor introduced thereinto; a composition for combination therapy including the antibody or the antigen-binding fragment thereof; a composition for preventing or treating cancer; and a method for preventing or treating cancer.

The invention relates to the technical field of biology, in particular to a human CD4 and TGF-beta1 / 2 / 3 combined bispecific antibody which at least comprises a first protein functional area, and the first protein functional area comprises a first antigen binding site targeting CD4; and the second protein functional region comprises a second antigen binding site targeting TGF (Transforming Growth Factor)-beta 1 / 2 / 3. The bispecific antibody disclosed by the invention can be well and specifically combined with CD4 and specifically combined to helper T cells; meanwhile, the bispecific antibody can be combined with TGF beta 1, so that Th1 cell mediated cellular immunity is activated, TGF beta 2 and TGF beta 3 are neutralized, and the bispecific antibody has the effect of preparing the medicine for preventing and treating bacterial infectious diseases.

Disclosed herein are methods of treating autoimmune, allergic, and / or inflammatory diseases in a subject in need thereof, comprising administering a therapeutic agent comprising one or more antigen-binding sites on a cell involved in the autoimmune, allergic, and / or inflammatory diseases and depleting the cell.

The problem to be solved by the present invention is to provide more and better options for treating any solid tumor with high frequency microsatellite instability (high frequency MSI or MSI-H) alterations, cervical cancer, endometrial cancer, lung cancer, brain cancer and breast cancer.SOLUTION: The present invention relates to multispecific antibodies comprising an antigen binding site that binds an extracellular part of CD137 and an antigen binding site that binds an extracellular part of a second membrane protem for use in a method of treatment of cancers in a subject in need thereof. The invention further relates to such multispecific antibodies, as well as methods and other aspects related thereto.SELECTED DRAWING: None

Anti-CD47 / anti-TIGIT bispecific antibody, a preparation method thereof and application thereof. The bispecific antibody comprises: (a) a first antigen binding part, comprising heavy chain variable region (VH) and light chain variable region (VL), VH and VL forming an antigen binding site that specifically binds to CD47; and (b) a second antigen binding part, comprising a single domain antibody (sdAb) that specifically binds to TIGIT, wherein the first antigen binding part and the second antigen binding part are fused with each other. The bispecific antibody can block two modes of tumor immune escape at the same time, thus having a good effect in tumor immunotherapy.

The present application relates to a kind of multispecific and / or multivalent binding protein for preventing and / or treating HIV infection, it includes at least 3 antigen binding sites, part of antigen binding site is specifically bound HIV-1-gp41 or HIV-1-gp120 or HIV-1-gp160, still part of antigen binding site is specifically bound human CD4 receptor or human CCR5 receptor;The binding protein of the present application has excellent broad-spectrum neutralizing ability in the treatment or prevention of HIV infection, provides a new solution for the problem of drug resistance escape caused by HIV virus variation, in addition, the present application inventor also unexpectedly found that the binding protein of the present application can treat or prevent the tumor-related disease caused by HIV infection.

Disclosed herein are chimeric antigen receptors (CARs) comprising an antigen binding site that recognizes citrullinated polypeptides. Citrullinated polypeptides, such as citrullinated vimentin, are expressed in the skin lesions of subjects with hidradenitis suppurativa. Further disclosed are T cells, and in particular, Treg cells that express these CARs. Administration of these CAR-T cells is useful in the treatment of hidradenitis suppurativa.

The present invention provides CAR-T cells constructed based on the natural protein TSH. The present invention also provides chimeric antigen receptor (TAR) CAR-T cells constructed based on the tandem structure of the TSH α and β subunits, and uses thereof. The TSHαβ-CAR-T cells of the present invention can target and kill TSHR-positive thyroid cancer cells and are non-immunogenic, making them promising candidates for the treatment of thyroid cancer.

The present disclosure relates generally to binding proteins comprising an antigen binding site, a T cell receptor binding site, and a T cell costimulatory molecule binding site. The disclosure also relates to pharmaceutical compositions comprising such binding proteins, nucleic acid molecules encoding such binding proteins and vectors comprising such nucleic acid molecules. The disclosure also relates to methods of treating a disorder or condition using such binding proteins and pharmaceutical compositions, binding proteins and pharmaceutical compositions for use in the treatment of a disorder or condition, and the use of such binding proteins and pharmaceutical compositions for the manufacture of a medicament for the treatment of a disorder or condition.

The present invention provides a chimeric antigen-receptor targeting LRRC15, which exhibits drug efficacy against tumors associated with LRRC15 positive cells, and cells comprising the same.SOLUTION: To provide a chimeric antigen-binding receptor containing an anti- LRRC15 antigen-binding site containing a specific CDR, and to provide chimeric antigen-binding receptor-expressing cells containing the receptor.SELECTED DRAWING: None

To provide an alternative antibody therapy targeting glycan epitopes.SOLUTION: Provided is an antibody or antigen-binding portion thereof that binds to sialyl Lewis A (sLeA) and sialyl Lewis C (sLeC), wherein the binding affinity of the antibody or antigen-binding portion to sLeA is a KD of 60 μ M or less and the binding affinity to sLeC is a KD of 100 μ M or less. Also provided are polynucleotides, vectors, host cells, pharmaceutical compositions, and methods related thereto.SELECTED DRAWING: Figure 2C

The present invention provides a multispecific antibody having at least one conditional activity and a method for producing the same. [Solution] A multispecific antibody comprises at least one binding site for a cell-specific antigen and at least one binding site for a tumor-reactive lymphocyte antigen, and the multispecific antibody comprises an IgG antibody or fragment thereof that binds to a first antigen; and at least one scFv antibody that binds to a second antigen different from the first antigen and is ligated to the C-terminus of at least one light chain or heavy chain of the IgG antibody or fragment. This multispecific antibody reversibly binds to the cell-specific antigen and the tumor-reactive lymphocyte antigen or at least one of the first antigen and the second antigen with greater affinity under abnormal conditions than under normal physiological conditions. Conjugates of multispecific antibodies and methods for producing multispecific antibodies are also provided.

This provides antibodies usable in pre-targeted radioimmunotherapy (PRIT) and radioimmunoimaging. [Solution] A multispecific antibody is provided for use in therapy, comprising an antigen-binding site specific to DOTAM-lead (Pb) chelate and an antigen-binding site specific to a target antigen.

To provide a method for delivering a therapeutic protein to the central nervous system for antibody-based therapy.SOLUTION: A method of expressing a bivalent binding member in a cell of the nervous system, the method comprising introducing into the cell an expression cassette encoding a polypeptide comprising an antibody heavy chain variable domain (VH), an antibody light chain variable domain (VL) and an IgGFc region, wherein the VH and the VL form an antigen binding site which specifically binds to a target protein, and wherein two molecules of the polypeptide, when expressed in a cell, form a disulphide-linked homodimeric bivalent binding member specific for the target protein.SELECTED DRAWING: None

The present invention includes proteins, nucleic acids and methods of making and using an activatable antibody (aAb) comprising, in order, the following structure: a first light chain comprising: a first variable light region; a cleavable linker; a first heavy chain comprising: a first variable heavy region; wherein the cleavable linker prevents or reduces the first light chain and the first heavy chain from forming a first antigen binding site against a first antigen; and wherein cleavage of the cleavable linker releases the first heavy chain to allow formation of the first antigen binding site to bind a first antigen.

The invention relates to the technical field of biology, in particular to a CD4 / TGF-beta1 binding bispecific antibody which at least comprises a first protein functional area and a second protein functional area, the first protein functional area comprises a first antigen binding site targeting CD4, the first antigen binding site can bind to the 77th site, the 79th site, the 96th site, the 121st-124th site of polypeptide shown as SEQ ID NO: 19, and the second antigen binding site can bind to the 124th-124th site of polypeptide shown as SEQ ID NO: 19. The 127th to 134 amino acids and the 163rd amino acids; and the second protein functional region comprises a second antigen binding site targeting TGF beta 1. The bispecific antibody disclosed by the invention can be well and specifically combined with CD4 and specifically combined to helper T cells; meanwhile, the bispecific antibody can be combined with the TGF beta 1 and is not combined with the TGF beta 2 and the TGF beta 3, so that cardiotoxicity caused by the TGF beta 2 and the TGF beta 3 is avoided. The invention has the effect of preparing medicines for preventing and treating fatty liver.

Provided herein are methods for making, and epitope-targeted, conditionally-activated, pro-drug, antibody, comprising: complementarity determining regions (CDRs) from an antibody identified from an in vivo, in vitro, or in silico antibody library; one or more engineered epitope masks connected to a linker, wherein the linker comprises a peptide, a polymer, or a chemical-linker that is cleaveable in vivo at a target site by an enzyme or cleaved chemically, and wherein the one or more engineered epitope masks binds the epitope-specific antibody at the CDRs of the epitope-specific antibody; and wherein the one or more engineered epitope masks linked to the antibody via the linker, wherein the masks are conditionally bound to the CDRs of the epitope-specific antibody, and wherein cleavage of the linker releases the one or more engineered epitope masks from the antigen binding site.

The invention relates to bispecific antigen binding proteins (ABP), such as bispecific antibodies, that bind with a first antigen binding site to both leukocyte immunoglobulin-like receptor subfamily B1 (LILRB1) and LILRB2 while not binding to, or binding with significantly less affinity to, leukocyte immunoglobulin-like receptor subfamily A (LILRA). The bispecific ABP of the invention bind with a second antigen binding site to immune checkpoint (molecules) such as PD-1 or PD-L1. The bispecific ABP of the invention can also inhibit the interaction between LILRB1 and / or LILRB2 and a natural ligand of ULRB receptors (e.g. interacting proteins, such as HLA-G) on immune cells and the inhibition of such interaction can reduce immune cell suppression and thereby support anti-infection and anti-tumour immune responses in a subject suffering from such diseases. Bispecific molecules combining LILRB1 / 2 antagonism with inhibition of immune checkpoints, such as the inhibition of the PD-1 / PD-L1 axis, is specifically useful in the treatment of proliferative disorders. Also provided are methods of reducing the immune suppression of cells involved with a cell-mediated immune response, and / or methods for treating infective- and / or proliferative diseases, using an LILRB1 and / or LILRB2 antigen binding protein such as an antibody binding to both LILRB1 and / or LILRB2, as well as certain related aspects including detection, diagnostic and screening methods.

A bispecific antibody that includes a first antigen binding site that is specific for a death receptor 5 (DR5) polypeptide and a second antigen binding site that is specific for a folate receptor alpha-1 (FOLR1) polypeptide, wherein the bispecific antibody includes: (i) a heavy chain amino acid sequence that includes SEQ ID NO:1 and a light chain amino acid sequence that includes SEQ ID NO:2; (ii) a heavy chain amino acid sequence that includes SEQ ID NO:11 and a light chain amino acid sequence that includes SEQ ID NO:2; (iii) a heavy chain amino acid sequence that includes SEQ ID NO:5 and a light chain amino acid sequence that includes SEQ ID NO: 6; or (iv) an scFv fragment that includes a knob-into-hole structure comprising SEQ ID NOs: 3 and 4.

The invention provides a bispecific antibody aiming at IL6R (Interleukin-6 Receptor) and TNF (Tumor Necrosis Factor) alpha and application of the bispecific antibody. The bispecific antibody comprises a first structural domain and a second structural domain, wherein the first structural domain is specifically combined with an interleukin-6 receptor IL-6R, and the second structural domain is specifically combined with a tumor necrosis factor-alpha. Compared with a monoclonal antibody, the double antibodies have the advantages that a specific antigen binding site is added, so that the specificity is higher, tumor cells can be targeted more accurately, adverse reactions caused by off-target toxicity are reduced, a special function is exerted, biological functions which are difficult to achieve by monoclonal antibody drugs are achieved, and compared with a monoclonal antibody combination therapy, the treatment cost can be effectively reduced, and the treatment effect is better. The upper limit of the curative effect on autoimmune diseases such as rheumatoid arthritis at present is broken through.

The invention relates to the field of therapeutic antibodies for the treatment of a subject with castration-resistant prostate cancer. More in particular it relates to treating castration-resistant prostate cancer using a bispecific antibody that comprises an antigen binding site that can bind an extracellular part of ERBB2 and an antigen binding site that can bind an extracellular part of ERBB3. Also, it relates to treating castration-resistant prostate cancer using an antibody that comprises an antigen binding site that can bind an extracellular part of ERBB3. The invention also relates to treating castration-resistant prostate cancer using a combination of one of said antibodies and an androgen receptor axis-targeting agent.

The invention relates to antigen binding sites, antibodies and fragments thereof, as well as compositions, kits and uses thereof for the treatment, attenuation and / or prevention of human immunodeficiency virus type 1 (HIV-1).

The invention relates to the technical field of biological information, in particular to a nanometer antibody and antigen interaction prediction method and device.The method comprises the steps that sequence characteristics of nanometer antibodies and antigens are obtained on the basis of a protein large language model, so that the initial nanometer antibody and antigen interaction probability is generated, and an antigen binding site prediction model is used for predicting the nanometer antibody and antigen interaction probability. Determining an estimated antigen binding site of the sequence features of the nano antibody and the antigen, extracting a corresponding target feature, fusing the target feature with the obtained sequence features, and updating the initial interaction probability of the nano antibody and the antigen by using the fused feature, so as to obtain a final prediction result of the interaction of the nano antibody and the antigen. According to the method provided by the invention, the importance of amino acid sites on a binding interface is highlighted when the interaction between the nano antibody and the antigen is predicted, and the prediction performance of the interaction between the nano antibody and the antigen is remarkably improved by the method.

Provided herein are methods for making epitope-targeted, conditionally activated pro-antibodies comprising: complementarity determining regions (CDRs) from an antibody identified from an in vivo, in vitro, or in silico antibody library; and one or more engineered epitope masks linked to a linker, wherein the linker comprises a peptide, polymer, or chemical linker that can be cleaved in vivo at a target site by an enzyme or chemically, and wherein the one or more engineered epitope masks bind to an epitope-specific antibody at a CDR of the epitope-specific antibody; and the one or more engineered epitope masks are linked to the antibody via the linker, wherein the mask is conditionally bound to the CDR of the epitope-specific antibody, and wherein cleavage of the linker releases the one or more engineered epitope masks from the antigen binding site.

To provide conjugates useful for targeting cancers in which HER2 is overexpressed.SOLUTION: Provided are dendrimer-targeting agent conjugates comprising a dendrimer, a HER2 targeting agent, and a therapeutic agent, wherein the dendrimer comprises a core unit and a lysine or lysine analog building unit, the HER2 targeting agent is a peptide moiety having a molecular weight of up to about 80kDa and comprising an antigen binding site, covalently linked by a spacer group, and the therapeutic agent is covalently linked to surface building units of the dendrimer.SELECTED DRAWING: Figure 1

The present invention provides a CAR-T cell constructed on the basis of a natural protein TSH. The present invention provides a chimeric antigen receptor constructed on the basis of a TSHα subunit and TSHβ subunit tandem structure, a CAR-T cell, and a use thereof. The TSHαβ-CAR-T cell of the present invention can kill TSHR-positive thyroid cancer cells in a targeted manner, and has no immunogenicity, so that the TSHαβ-CAR-T cell has the prospect of being used in the treatment of thyroid cancer.